CRISPR and AI-driven gene-target discovery are converging with NASA and startup-built space agriculture systems, creating a new frontier at the intersection of biotech and deep-space food autonomy.
The FDA cleared the first AI software for hemorrhage triage in combat casualties — an Android app that stratifies bleeding risk in 10 minutes using only heart rate and blood pressure. Validated on 5,895 patients across 8 medical centers.
The four metrics that institutional biotech funds actually use, the three red flags that kill deals at Series A, and how to verify a founder's claims without relying on the pitch deck.
Astroscale, ClearSpace, Starfish Space, and D-Orbit are turning orbital cleanup into a commercial market. With $1.35B projected for 2026, FCC deorbit mandates, and the first robotic capture missions moving past demonstration, the sector is crossing from government contracts into real revenue.
The Munich-based drone maker raised $1.2 billion at an $8 billion valuation, backed by Blackstone and Airbus, and is already profitable — a rarity in defense tech.
MGX, the Abu Dhabi investment firm backed by Mubadala and G42, has closed Fund I at $49 billion — above target — with a portfolio spanning OpenAI, Anthropic, xAI, and $40 billion in data centre infrastructure.
The satellite startup that bet against the small-satellite orthodoxy and won $500M+ in Pentagon and commercial contracts before its first operational delivery.
Isomorphic Labs raised $2.1B to scale its IsoDDE AI drug design engine toward first-in-human clinical trials by end of 2026.